Xiliertinib

DB21453InvestigationalSmall molecule

Xiliertinib is a small molecule drug. The usage of the INN stem '-ertinib' in the name indicates that Xiliertinib is a epidermal growth factor receptor (EGFR) inhibitor. Xiliertinib is under... Xiliertinib is under investigation in clinical trial NCT02601274 (Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor).

Mechanism: Pharmacologically active on Epidermal growth factor receptor
Curator reviewed
Formula / weight: C₂₅H₂₆N₆O₂ · 442.523 g/mol (avg)
Code names: HMPL-309

Resolves to

Compound

UNII6ZZ3B7NZ0BCAS1353644-70-8ChEMBLCHEMBL5314410ChEBI759123PubChem54759275

Structure

InChIKeyFSXCKIBROURMFT-VGSWGCGISA-NSMILES[H][C@]12CCN(C)[C@@]1([H])CN(C2)C(=O)NC1=CC2=C(NC3=CC(=CC=C3)C#C)N=CN=C2C=C1OC

Targets

P00533EGFR

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Xiliertinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account